Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3128046 | 0.98 | FFAR1 (0.63) | FFAR1KEAP1CA1CA2GFER | |
| SCHEMBL27544320 | 0.98 | FFAR1 (0.63) | FFAR1KEAP1CA1CA2GFER | |
| SCHEMBL8339608 | 0.94 | FFAR1 (0.71) | FFAR1KEAP1CA1CA2GFER | |
| SCHEMBL69746 | 0.88 | FFAR1 (0.81) | FFAR1KEAP1CA1CA2FFAR4 | |
| SCHEMBL434792 | 0.87 | SMN1; SMN2 (0.67) | FFAR1KEAP1GFERMAOBMAOA | |
| SCHEMBL4845038 | 0.86 | FFAR1 (0.65) | FFAR1KEAP1CA1CA2FFAR4 | |
| SCHEMBL4600571 | 0.86 | CYP19A1 (0.68) | FFAR1KEAP1FFAR4MAOBMAOA | |
| Hydrochloric Acid SCHEMBL25264643 | 0.85 | FFAR1 (0.77) | FFAR1KEAP1CA1CA2FFAR4 | |
| SCHEMBL224789 | 0.85 | MAPT (0.66) | FFAR1GFERMAOBMAOA | |
| Hydrochloric Acid SCHEMBL11105604 | 0.84 | FFAR1 (0.63) | FFAR1KEAP1CA1CA2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| CN-119707842-A | Proteome targeting labeling capture probe and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2025-03-28 | — | — | CN | claimed |
| CN-119591822-A | Polytetrahydrofuran ether amine polyurea with high elongation at break and preparation method and application thereof | 北京九天行歌航天科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-110707221-B | Application of amino acid ionic liquid in preparation of perovskite layer in perovskite photoelectric device | 北京大学深圳研究生院 | 2023-09-01 | — | — | CN | claimed |
| CN-115724818-A | Coix seed zearalenone enzyme-linked immunosorbent assay kit and method | 中国中医科学院中药研究所 | 2023-03-03 | — | — | CN | claimed |
| CN-114456438-B | Composite material for enriching viruses in droplets and application thereof | 四川大学 | 2022-11-22 | — | — | CN | claimed |
| CN-113185760-B | Functionalized nano-epoxy isoprene rubber and application thereof in aircraft tires | 中国科学院长春应用化学研究所 | 2022-06-07 | — | — | CN | claimed |
| CN-114456438-A | Composite material for enriching viruses in droplets and application thereof | 四川大学 | 2022-05-10 | — | — | CN | claimed |
| CN-114315817-A | Meloxicam hapten and artificial antigen as well as preparation methods and application thereof | 中国农业大学 | 2022-04-12 | — | — | CN | claimed |
| US-20070027292-A1 | N-hydroxyalkyltrimellitimide esters and bis-(trimellitimide) esters and method of making | INEOS CALABRIAN CORPORATION (GB) | 2007-02-01 | — | — | US | claimed |
| EP-1620457-A2 | INDUCERS OF RECOMBINANT PROTEIN EXPRESSION | Immunex Corporation (US) | 2006-02-01 | — | — | EP | claimed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | claimed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | claimed |
| US-20040265964-A1 | Inducers of recombinant protein expression | IMMUNEX CORPORATION | 2004-12-30 | — | — | US | claimed |
| WO-2004096833-A2 | INDUCERS OF RECOMBINANT PROTEIN EXPRESSION | IMMUNEX CORPORATION (US) | 2004-11-11 | — | — | WO | claimed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | claimed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | claimed |
| US-5238909-A | For preemergence or postemergence use | EASTMAN KODAK COMPANY (US) | 1993-08-24 | — | — | US | claimed |
| EP-0476761-A1 | 4-substituted isoxazoles | EASTMAN KODAK COMPANY (US) | 1992-03-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265964-A1 | Inducers of recombinant protein expression | AADAC, CRYAA, PMAIP1 | FFAR1 2596/4885KEAP1 4086/4885CA1 80/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | FFAR1 2626/4885KEAP1 2843/4885CA1 4778/4885 |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | CXCR2, FPR1, CCR2 | FFAR1 24/4885KEAP1 2664/4885CA1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.